Companies › J-Pharma
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology, Other; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nanvuranlat | – | Phase 3 | Advanced Biliary Tract Cancer | Oct 2027 |
| JPH034 | – | Phase 1 | Health Adult Subjects | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07534657 | JPH034 | Phase 1 | Health Adult Subjects | Other | Oct 2026 |
| NCT07265674 | Nanvuranlat | Phase 3 | Advanced Biliary Tract Cancer | Oncology | Oct 2027 |
No annotated target.
–
Relay Therapeutics Haihe Biopharma Onconic Therapeutics Monte Rosa Therapeutics Beijing Tide Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.